 Connection
Katja Kiseljak-Vassiliades to Protein Kinase Inhibitors
This is a "connection" page, showing publications Katja Kiseljak-Vassiliades has written about Protein Kinase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.737 |
|
|
|
-
Kar A, Banerjee T, Pozdeyev N, Holmstoen TB, Foust LJ, Bagby SM, Pitts TM, Habra MA, Wierman ME, Kiseljak-Vassiliades K. Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma. Endocrinology. 2026 Sep 03; 167(10).
Score: 0.608
-
Xiong W, Matheson CJ, Xu M, Backos DS, Mills TS, Salian-Mehta S, Kiseljak-Vassiliades K, Reigan P, Wierman ME. Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors. Mol Cancer Ther. 2016 Mar; 15(3):412-20.
Score: 0.073
-
Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 01; 118(21):5302-9.
Score: 0.056
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|